| Literature DB >> 23306172 |
Ibtissem Djinni1, Andrea Defant, Mouloud Kecha, Ines Mancini.
Abstract
Polyketide 13 [=2-hydroxy-5-((6-hydroxy-4-oxo-4H-pyran-2-yl)methyl)-2- propylchroman-4-one] and three related known compounds 7, 9 and 11 were obtained and structurally characterized from Streptomyces sundarbansensis strain, an endophytic actinomycete isolated from the Algerian marine brown algae Fucus sp. Compound 13 was obtained as the major metabolite from optimized culture conditions, by using Agar state fermentation. Due to tautomeric equilibrium, 13 in CD(3)OD solution was able to incorporate five deuterium atoms, as deduced by NMR and ESI-MS/MS analysis. The 2-hydroxy-γ-pyrone form was established for these metabolites based on the comparison of their experimental IR spectra with the DFT calculated ones, for both the corresponding 4-hydroxy-α-pyrone and 2-hydroxy-γ-pyrone forms. During antibacterial evaluation, compound 13 stood out as the most active of the series, showing a selective activity against the gram positive pathogenic methicillin-resistant S. aureus (MRSA, MIC = 6 μΜ), with a bacteriostatic effect.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23306172 PMCID: PMC3564162 DOI: 10.3390/md11010124
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Molecular structures of some polyketides. Arbitrary numbering is for convenience.
Figure 2Molecular structure of compound 13 and its derivative by incorporation of deuterium atoms. Numbering is for convenience.
NMR spectroscopic data for compound 13 (400 MHz, in CDCl3 and CD3OD). δ in ppm, J in Hz.
| Position | δH (CD3OD) | δH (CDCl3) | δC, (CDCl3) | HMBC a |
|---|---|---|---|---|
| 1 | – | – | 165.4 | |
| 2 | – | 5.33, s | 89.9 | 3, 4, 5 |
| 3 | 171.3 | |||
| 4 | 5.65, s | 5.75, s | 101.2 | |
| 5 | 166.9 | |||
| 6 | 4.23, dd(16.2) | 4.20, d(16.4) | 38.6 | 1, 4, 8, 12 |
| 4.32, dd(16.2) | 4.28, d(16.4) | |||
| 7 | 133.5 | |||
| 8 | 6.99, d (8.6) | 6.99, s | 125.2 | |
| 9 | 7.48, t (8.1) | 7.39, t (8.2) | 135.4 | 7, 11 |
| 10 | 6.93, d (7.2) | 6.90, d(8.2) | 118.4 | 8, 11, 12 |
| 11 | 158.1 | |||
| 12 | 118.5 | |||
| 13 | 194.0 | |||
| 14 | – | 2.79, d (16.0) | 47.1 | 12,13,15, 16 |
| – | 2.89, d (16.0) | |||
| 15 | 102.3 | |||
| 16 | 1.89, m | 1.88, m | 43.1 | 14, 15, 17, 18 |
| 17 | 1.53, m | 1.57, m | 17.1 | 15, 16, 18 |
| 17 | 1.00, t (7.0) | 0.99 (t, 7.0) | 14.04 | 17, 16 |
a HMBC correlations are from protons(s) in the line with the indicated carbon(s).
DFT calculated stretching frequencies (in cm−1) for the carbonyl groups in α-pyrone (A) and γ-pyrone (B) forms and experimental values for 7, 9 and 13 and 4-hydroxy-6-methyl-2H-pyran-2-one as reference compound. Arbitrary numbering on A and B forms is for convenience.
| νIRcalcd | |||||
|---|---|---|---|---|---|
| Compound | νIRexp. | C(1)=O | C(13)=O a | C(3)=O | C(13)=O a |
| 7 | 1637 | 1780 | 1639 | 1686 | 1642 |
| 1620 | |||||
| 1578 | |||||
| 1524 | |||||
| 9 | 1699 | 1780 | 1649 | 1683 | 1662 |
| 1645 | |||||
| 1607 | |||||
| 1598 | |||||
| 13 | 1689 | 1782 | 1678 | 1682 | 1698 |
| 1649 | |||||
| 1603 | |||||
| 1593 | |||||
| R=CH3b | 1738 | 1782 | – | 1692 | – |
| 1645 | |||||
| 1534 | |||||
a According to numbering in the structures reported in Figure 1; b Experimental values from [20].
Minimum Inhibitory Concentration (MIC) values of compounds 9, 11 and 13 on some pathogenic strains.
| MIC (μg/mL) | |||
|---|---|---|---|
| Compounds | MRSA ATCC 43300 | ||
|
| – | >32 | >32 |
|
| >32 | >32 | >32 |
|
| 16 | 2 | >32 |
| Vancomycin | – | <2 | – |
| Gentamicin | <2 | <2 | – |